MX2022009870A - Ácidos ribonucleicos (arn) para la inhibición del complemento. - Google Patents
Ácidos ribonucleicos (arn) para la inhibición del complemento.Info
- Publication number
- MX2022009870A MX2022009870A MX2022009870A MX2022009870A MX2022009870A MX 2022009870 A MX2022009870 A MX 2022009870A MX 2022009870 A MX2022009870 A MX 2022009870A MX 2022009870 A MX2022009870 A MX 2022009870A MX 2022009870 A MX2022009870 A MX 2022009870A
- Authority
- MX
- Mexico
- Prior art keywords
- rna
- ribonucleic acids
- complement inhibition
- complement
- inhibition
- Prior art date
Links
- 230000000295 complement effect Effects 0.000 title abstract 2
- 229920002477 rna polymer Polymers 0.000 title 2
- 230000005764 inhibitory process Effects 0.000 title 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 abstract 1
- 108020004459 Small interfering RNA Proteins 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 108091070501 miRNA Proteins 0.000 abstract 1
- 239000002679 microRNA Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062977012P | 2020-02-14 | 2020-02-14 | |
| US202062980100P | 2020-02-21 | 2020-02-21 | |
| US202063062321P | 2020-08-06 | 2020-08-06 | |
| PCT/US2021/018071 WO2021163654A1 (en) | 2020-02-14 | 2021-02-13 | Rnas for complement inhibition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022009870A true MX2022009870A (es) | 2022-11-07 |
Family
ID=77292725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022009870A MX2022009870A (es) | 2020-02-14 | 2021-02-13 | Ácidos ribonucleicos (arn) para la inhibición del complemento. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230095695A1 (https=) |
| EP (1) | EP4103716A4 (https=) |
| JP (1) | JP2023514570A (https=) |
| KR (1) | KR20220155301A (https=) |
| CN (1) | CN115335524A (https=) |
| AU (1) | AU2021221035A1 (https=) |
| CA (1) | CA3170158A1 (https=) |
| IL (1) | IL295517A (https=) |
| MX (1) | MX2022009870A (https=) |
| WO (1) | WO2021163654A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11510939B1 (en) | 2019-04-19 | 2022-11-29 | Apellis Pharmaceuticals, Inc. | RNAs for complement inhibition |
| WO2022226127A1 (en) * | 2021-04-20 | 2022-10-27 | Alexion Pharmaceuticals, Inc. | Compositions and methods for inhibiting complement component 3 expression |
| EP4398926A4 (en) * | 2021-09-09 | 2025-07-02 | Apellis Pharmaceuticals Inc | TREATMENT OF GEOGRAPHIC ATROPHY |
| WO2024092105A2 (en) | 2022-10-27 | 2024-05-02 | Arrowhead Pharmaceuticals, Inc. | Rnai agents for inhibiting expression of complement component c3 (c3), pharmaceutical compositions thereof, and methods of use |
| CN121488036A (zh) * | 2023-07-21 | 2026-02-06 | 上海舶望制药有限公司 | 用于抑制补体成分3(c3)表达的组合物和方法 |
| WO2025026124A1 (zh) * | 2023-08-03 | 2025-02-06 | 苏州炫景生物科技有限公司 | C4b基因抑制剂组合物及其应用 |
| WO2025179182A2 (en) * | 2024-02-22 | 2025-08-28 | Apellis Pharmaceuticals, Inc. | C3 targeted inhibitory rna |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2670801A1 (en) * | 2005-11-30 | 2007-06-07 | Intradigm Corporation | Compositions and methods of using sirna to knockdown gene expression and to improve solid organ and cell transplantation |
| WO2007124452A2 (en) * | 2006-04-20 | 2007-11-01 | The Regents Of The University Of California | Methods for expressing multiple sirna and shrna from a single vector |
| IL288931B2 (en) * | 2013-03-14 | 2025-05-01 | Alnylam Pharmaceuticals Inc | Compositions comprising a complementary portion of C5 IRNA and methods of using them |
| RU2019113301A (ru) * | 2016-10-17 | 2020-11-17 | Апеллис Фармасьютикалс, Инк. | Комбинированная терапия для ингибирования с3 |
| SG11202002940QA (en) * | 2017-11-01 | 2020-04-29 | Alnylam Pharmaceuticals Inc | Complement component c3 irna compositions and methods of use thereof |
-
2021
- 2021-02-13 IL IL295517A patent/IL295517A/en unknown
- 2021-02-13 MX MX2022009870A patent/MX2022009870A/es unknown
- 2021-02-13 KR KR1020227031848A patent/KR20220155301A/ko active Pending
- 2021-02-13 US US17/798,339 patent/US20230095695A1/en active Pending
- 2021-02-13 JP JP2022548899A patent/JP2023514570A/ja active Pending
- 2021-02-13 WO PCT/US2021/018071 patent/WO2021163654A1/en not_active Ceased
- 2021-02-13 AU AU2021221035A patent/AU2021221035A1/en active Pending
- 2021-02-13 CA CA3170158A patent/CA3170158A1/en active Pending
- 2021-02-13 CN CN202180024287.XA patent/CN115335524A/zh active Pending
- 2021-02-13 EP EP21754090.5A patent/EP4103716A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023514570A (ja) | 2023-04-06 |
| EP4103716A1 (en) | 2022-12-21 |
| EP4103716A4 (en) | 2025-07-09 |
| CN115335524A (zh) | 2022-11-11 |
| CA3170158A1 (en) | 2021-08-19 |
| IL295517A (en) | 2022-10-01 |
| WO2021163654A1 (en) | 2021-08-19 |
| KR20220155301A (ko) | 2022-11-22 |
| AU2021221035A1 (en) | 2022-09-08 |
| WO2021163654A8 (en) | 2021-10-21 |
| US20230095695A1 (en) | 2023-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022009870A (es) | Ácidos ribonucleicos (arn) para la inhibición del complemento. | |
| CL2023002870A1 (es) | Composiciones de arni contra el angiotensinógeno (agt) y métodos para su uso | |
| CL2017001956A1 (es) | Oligomeros antisentido de tau y uso de los mismos | |
| MX2025007610A (es) | Composiciones de arni de 17beta-hidroxiesteroide deshidrogenasa tipo 13 (hsd17b13) y metodos de uso de las mismas | |
| MX2024008022A (es) | Composiciones y kits para el tratamiento de la hemofilia a o b. | |
| MX389425B (es) | Exosomas que comprenden agentes terapeuticos de arn | |
| CO2018000134A2 (es) | Factor ix modificado, y composiciones para la transferencia de genes a células, órganos y tejidos | |
| CO2019003846A2 (es) | Tratamiento aav de la enfermedad de huntington | |
| CL2020001810A1 (es) | Oligonucleótidos antisentido para alfa-sinucleína y usos de los mismos. | |
| CO2017004728A2 (es) | Composiciones y métodos para inhibir la expresión del gen hao1 (hidroxiácido-oxidasa 1 (glicolato-oxidasa) | |
| MX385048B (es) | Composiciones y metodos para inhibir la expresion del gen alas1. | |
| AR102777A1 (es) | COMPOSICIONES DE ARNi CONTRA TMPRSS6 Y MÉTODOS PARA SU USO | |
| MX2022000183A (es) | Lipidos cationicos y usos de estos. | |
| AR091539A1 (es) | INHIBIDORES DE LA FAMILIA miR-15 DE MICRO-ARN | |
| CO2024006020A2 (es) | Composiciones y métodos para inhibir la expresión de la proteína angiotensinógeno (agt) | |
| WO2022072950A8 (en) | NUCLEOSIDE CONTAINING siRNAS FOR TREATING VIRAL DISEASES | |
| CL2025000194A1 (es) | Construcciones de arni para inhibir expresión de scap y sus usos | |
| MX381947B (es) | Mirna natural para controlar la expresion de gen y uso del mismo. | |
| CL2022001481A1 (es) | Composiciones de ácidos nucleicos | |
| MX2020008242A (es) | Promotor especifico de oligodendrocitos, mirna especifico para el gen de plp1, vector que incluye el promotor y/o mirna, y composicion farmaceutica que incluye el vector. | |
| MX2024011595A (es) | Constructos de arni para inhibir la expresion de pnpla3 y metodos de uso de los mismos | |
| CL2024001214A1 (es) | Constructos de arni para inhibir la expresión de gpam y métodos de uso. | |
| MX2024014428A (es) | Constructos de arni para inhibir la expresion de scap y metodos de utilizacion de los mismos | |
| RU2014145910A (ru) | Способы воздействия на экспрессию гена APOE | |
| RU2014142753A (ru) | Способы воздействия на экспрессию гена рецептора витамина D |